The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
#EHA2024: Phase III trials in multiple myeloma
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to phase III trials in multiple myeloma here.
CONGRESS #EHA2024 | @mvmateos @usal presents results from the phase III DREAMM-7 trial evaluating the safety and efficacy of BVd vs DVd in patients with R/R MM who received ≥1 prior line of therapy. BVd improved PFS and led to a greater depth of response vs DVd, with a… pic.twitter.com/Ex3hh99xkj
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | @ThierryFacon @univ_lille presents findings of the phase III IMROZ study (NCT03319667), evaluating efficacy and safety of Isa-VRd vs VRd in transplant-ineligible pts with NDMM (N=446). The study met its primary endpoint: 60-mo PFS rate was 63.2% with Isa-VRd… pic.twitter.com/huL9uJOaTt
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
CONGRESS #EHA2024 | Xavier Leleu, @CHU_de_Poitiers discusses results from the phase III BENEFIT/IFM2020-05 trial investigating the safety and efficacy of Isa-VRd vs Isa-Rd in transplant-ineligible patients with NDMM. Isa-VRd was associated with deep responses and an increased… pic.twitter.com/LGibzPTQTV
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
CONGRESS #EHA2024 | @RaabMarc @uniklinik_hd @HDMyeloma presents results from an interim analysis of the phase III GMMG-HD7 trial of Isa-VRd in transplant-eligible patients with NDMM. The addition of isatuximab to RVd induction was associated with improved response rates and MRD… pic.twitter.com/OHQSa23Yll
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
CONGRESS #EHA2024 | Philippe Moreau, @CHUnantes presents long-term outcomes from the phase III CASSIOPEIA trial of D-VTd followed by DARA maintenance in transplant-eligible patients with NDMM. D-VTd induction and consolidation plus DARA maintenance resulted in the most pronounced… pic.twitter.com/WoZ4aEgQBW
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
CONGRESS #EHA2024 | Pieter Sonneveld, @ErasmusMC highlights results from an MRD analysis of the phase III PERSEUS trial of D-VRd in transplant-eligible patients with NDMM:
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
· D-VRd + D-R increased the rates of deeper MRD-negativity vs VRd + R
· A greater proportion of MRD-positive… pic.twitter.com/c9AFQ3nUjk
CONGRESS #EHA2024 | Late-breaking | Meletios A. Dimopoulos @uoaofficial shares data from the DREAMM-3 trial of belantamab mafodotin malidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib dexamethasone (PVd) for RRMM. N=302, mFU=21.8. mPFS was NR vs 12.7 mo in the BPd… pic.twitter.com/xLqk3lOVBr
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS | POSTER | #EHA2024 | Niels van de Donk presents results from the phase III MAJESTEC-7 study evaluating teclistamab (TEC) + DR vs DR + DEX in patients with NDMM without ASCT, N=26. ORR 92.3% (≥80.8% CR, ≥92.3% VGPR). #mmsm #myeloma #MedicalCongress pic.twitter.com/2BjqiWKrEX
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content